Literature DB >> 2477560

Prostate specific antigen: not detectable despite tumor progression after radical prostatectomy.

D E Goldrath1, E M Messing.   

Abstract

Prostate specific antigen was not detectable in 2 men with documented prostate cancer progression after radical prostatectomy. Possible explanations for prostate specific antigen remaining zero in these situations are discussed. We conclude that while monitoring prostate specific antigen is of great value in the followup of patients with prostatic cancer, it has not replaced more standard means of followup.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2477560     DOI: 10.1016/s0022-5347(17)38998-x

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  5 in total

1.  Tibia metastasis without prostate specific antigen (PSA) increase following radical vesiculo-prostatectomy.

Authors:  J Hübler; F Sükösd; M Czipri
Journal:  Int Urol Nephrol       Date:  2000       Impact factor: 2.370

2.  Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer.

Authors:  C R Pound; M K Brawer; A W Partin
Journal:  Rev Urol       Date:  2001

3.  Maximal androgen blockade in combination with methotrexate for treatment of metastatic prostate cancer.

Authors:  P Sagaster; J Flamm; M Micksche; E Fritz; G Donner; H Ludwig
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

4.  Is DRE essential for the follow up of prostate cancer patients? A prospective audit of 194 patients.

Authors:  Narasimhan Ragavan; Vijay K Sangar; Sujoy Gupta; Jennifer Herdman; Shyam S Matanhelia; Michael E Watson; Rosemary A Blades
Journal:  BMC Urol       Date:  2005-01-10       Impact factor: 2.264

Review 5.  What does prostate-specific antigen recurrence mean?

Authors:  C R Pound; A W Partin
Journal:  Curr Urol Rep       Date:  2000-05       Impact factor: 2.862

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.